Last reviewed · How we verify

NCT02955446

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

NO LONGER AVAILABLE Last updated 1 February 2019
What this trial tests

trial testing PF-03084014 in Neoplasm. No longer available.

Quick facts

Lead sponsorUniversity of Colorado, Denver
StatusNO LONGER AVAILABLE
Study typeEXPANDED_ACCESS
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Colorado, Denver

Who can join

Adults 16 to 101, any sex, with Neoplasm or Desmoid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open label, non randomized, compassionate use protocol in patients with advanced solid tumor malignancies who were previously enrolled in the phase I study (NCT00878189) of this agent.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.
    Allen F, Maillard I. · · 2021 · cited 62× · PMID 34124039 · DOI 10.3389/fcell.2021.649205

Verify or expand the search:

Other trials of PF-03084014

Trials testing the same drug.

Other recruiting trials for Neoplasm

Currently open trials in the same condition.

Other University of Colorado, Denver trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02955446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing